Variables | No PAH (N = 17) | PAH (N = 19) | HD (N = 14) | p value§ |
---|---|---|---|---|
Age at serum sampling (years)* | 53.3 ± 11.6 | 64.0 ± 9.4 | 54.1 ± 10.4 | 0.009 |
Female | 15 (88) | 16 (84) | 15 (85) | 0.727 |
Race | Â | Â | Â | Â |
 White | 14 (82) | 16 (84) | 12 (80) | 0.881 |
 Black | 3 (18) | 3 (16) | 3 (20) | |
Smoking status | Â | Â | Â | Â |
 Never | 9 (53) | 10 (53) | 8 (53) | 0.280 |
 Past | 6 (35) | 9 (47) | 5 (33) | |
 Current | 2 (12) | 0 | 2 (13) | |
SSc types | Â | Â | Â | Â |
 Limited | 11 (65) | 16 (84) |  | 0.177 |
 Diffuse | 6 (35) | 3 (16) |  | |
mRSS* (range 0–51) | 5.5 ± 6.1 | 7.3 ± 10.3 |  | 0.567 |
SSc duration (RP onset)*, years | 14.0 ± 12.6 | 21.7 ± 9.4 |  | 0.008 |
SSc duration (1st non-RP symptom)*, years | 10.5 ± 7.3 | 18.5 ± 9.5 |  | 0.010 |
RP severity score* (range 0–4) | 1.6 ± 0.8 | 2.0 ± 1.0 |  | 0.194 |
Heart severity score* (range 0–4) | 0.2 ± 0.7 | 1.2 ± 1.7 |  | 0.062 |
Lung severity score* (range 0–4) | 1.1 ± 1.3 | 3.1 ± 1.3 |  | <0.001 |
Hemodynamics (RHC) | Â | Â | Â | Â |
 mPAP* (mm Hg) | NA | 35.2 ± 8.1 |  | NA |
 PCWP* (mm Hg) | NA | 11.5 ± 4.0 |  | NA |
FVC* (% predicted) | 81.9 ± 22.9 | 73.1 ± 9.9 |  | 0.149 |
DLCO* (% predicted) | 78.2 ± 23.0 | 48.7 ± 16.8 |  | <0.001 |
RLD†| 6 (35) | 6 (32) |  | 0.813 |
eRVSP* | 24.0 ± 6.3 | 65.2 ± 19.9 |  | <0.001 |
Autoantibody status | Â | Â | Â | Â |
 ACA | 4 (24) | 10 (53) |  | 0.07 |
 Anti-Scl-70 | 7 (41) | 1 (5) |  | 0.01 |
 Anti-RNA-polymerase 3 | 2 (12) | 0 |  | 0.124 |
Medication use (current) | Â | Â | Â | Â |
 Immunosuppressants‡ | 5 (29) | 5 (26) |  | 0.836 |
 Calcium channel blocker | 10 (59) | 7 (37) |  | 0.187 |
 Endothelin receptor antagonist | 1 (6) | 6 (32) |  | 0.052 |
 Phosphodiesterase 5 inhibitor | 4 (24) | 11 (58) |  | 0.037 |
 Prostanoid | 0 | 0 |  | NA |
 Statin | 6 (35) | 5 (26) |  | 0.559 |
 Aspirin | 5 (29) | 5 (26) |  | 0.836 |